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Abstract
Background: We previously showed that local use of periodate oxidized ATP (oATP, a selective
inhibitor of P2X7 receptors for ATP) in rat paw treated with Freund's adjuvant induced a significant
reduction of hyperalgesia Herein we investigate the role of oATP, in the rat paws inflamed by
carrageenan, which mimics acute inflammation in humans.
Results: Local, oral or intravenous administration of a single dose of oATP significantly reduced
thermal hyperalgesia in hind paws of rats for 24 hours, and such effect was greater than that
induced by diclofenac or indomethacin. Following oATP treatment, the expression of the pro-
inflammatory chemokines interferon-gamma-inducible protein-10 (IP-10), mon ocyte
chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) within the inflamed tissues markedly
decreased on vessels and infiltrated cells. In parallel, the immunohistochemical findings showed an
impairment, with respect to the untreated rats, in P2X7 expression, mainly on nerves and vessels
close to the site of inflammation. Finally, oATP treatment significantly reduced the presence of
infiltrating inflammatory macrophages in the paw tissue.
Conclusion: Taken together these results clearly show that oATP reduces carrageenan-induced
inflammation in rats.
Background
We previously showed the ability of the local treatment
with periodated oxidized ATP (oATP), an inhibitor of the
P2X7 ATP (adenosine 5'-triphosphate) receptor [1], to
relieve inflammatory pain in the rat paw, in which chronic
inflammation was induced by Freund's complete adju-
vant (CFA) injection [2,3]. There are two classes of ATP-
receptors, the ionotropic P2X receptors and the G-protein-
coupled P2Y receptors. Recently, these purinoceptors have
been extensively studied because of their important roles
in several ATP-mediated cellular functions [4]. In particu-
lar, there are seven subunits of P2X receptors (P2X1–7),
which are differently expressed by many cell types [4].
Some P2X receptors are expressed in DRG neurons [5].
ATP, released by neuronal and non-neuronal cells, is able
to initiate a pronociceptive signal through different P2X
subtypes of P2 purinoceptors [6]. The expression of P2X
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by subsets of primary afferent neurons plays a role in the
generation of pain from the periphery to the spinal cord
[7,8]. ATP seems to be involved in the initiation of
impulses in some sensory fibers [5]. In fact, excitation of
sensory neurons by ATP evokes a sensation of pain in
humans [9]. In rats, P2X receptor-mediated excitation of
nociceptive afferents in normal and arthritic knee joints
has been demonstrated [10]. Extracellular ATP exerts its
activity during inflammatory processes. In fact, ATP is
released by sensory nerves and by damaged cells during
inflammation and acts by exciting primary sensory neu-
rons [11,12].
P2X7 receptors for ATP have been demonstrated on
monocytes/macrophages, dendritic cells, mast cells,
fibroblasts and lymphocytes [13]. Such receptors mediate
the ATP cytolytic activity on macrophages [14,15]. We
showed the presence of P2X7 receptors also on subcutane-
ous sensory nerve terminals [3]. Thus, we hypothesized
that local antihyperalgesic effect of oATP was related to
the inhibition of pain transmission through the block of
P2X7 receptors, due to oATP.
In the present work we investigated the effect of oATP
treatment in the acutely carrageenan-inflamed rat hind
paws. The treatment was performed locally, orally, or
intravenously. The expression of the pro-inflammatory
chemokines interferon-gamma-inducible protein-10 (IP-
10), monocyte chemoattractant protein-1 (MCP-1) and
interleukin-8 (IL-8) in the paws was assessed. IP-10 is a
CXC-chemokine which regulates the recruitment of T cells
[16,17]. It has inhibitory activity on fibroblast migration
[18] and has been recently demonstrated to be a potent
angiostatic protein in vivo [19]. MCP-1 is a CC-chemok-
ine involved in the recruitment and activation of mono-
cyte and macrophage lineage cell; it is high in serum of
patients affected by both relapsing polychondritis and
rheumatoid arthritis [20]. It has been also recognized as
an angiogenic chemokine through the induction of VEGF
(vascular endothelial growth factor) -A gene expression
[21]. IL-8 is a CXC-chemokine which exerts potent chem-
otacting and stimulating activities on neutrophils. In fact,
it causes the neutrophil degranulation and the generation
of reactive oxygen intermediates, which are able to cause
tissue damage and to amplify the inflammatory response
[22]. We choosed to examine the expression of IL-8
because it is modulated during acute, carrageenan-
induced inflammation, characterized by neutrophil
recruitment. However, we also examined the expression
of IP-10 and MCP-1, which recruit T cells and monocytes/
macrophages, respectively, because such chemokines are
released by mastocytes, macrophages and fibroblasts resi-
dent in the inflamed tissue. Moreover, some inflamma-
tory mediators (histamine, thrombin, and cytokines as
TNFα) produced during acute inflammation can activate
endothelial cells, thus enabling them to produce and
release MCP-1 [23]. In parallel with chemokine expres-
sion, we investigated the expression of P2X7 receptors and
the presence of macrophage infiltrate in the paw tissue.
Finally, we evaluated the antinociceptive effect of oATP in
comparison with that obtained by two known antiinflam-
matory drugs, e.g. diclofenac and indomethacin. Our
results clearly show that oATP exerts both antinflamma-
tory and antihyperalgesic effects.
Results
Therapy with oATP reduces thermal hyperalgesia in rats
To test the potential role of oATP in reducing thermosen-
sation in vivo, we subjected rats to the paw withdrawal
latencies assay, and measured the intervals expressed in
second. In untreated rats the values of paw withdrawal
latencies averaged 12.0 ± 2.0, and were completely similar
to those obtained in paws locally treated with saline (11.9
± 1.0). oATP, administered using three different routes,
did not significantly influence such data (12.0 ± 0.8, when
administered locally; 11.9 ± 0.7, orally; 12.2 ± 0.9, intra-
venously; n = 7).
Following oATP administration, the rats were fully awake
and responsive to stimuli.
oATP administration reduced hind paw thermal hyperal-
gesia. Different doses of oATP dissolved in 0.15 ml saline
(50, 100, 200 µM) were administered either intra-
plantarly, orally or intravenously 3 hours after carra-
genaan injection into right hind paws. Paw withdrawal
latencies were measured 3 hours after oATP or saline
(vehicle) administration. oATP treatments all significantly
increased the antinociceptive score as revealed by an
increase in the withdrawal latency compared to basal
measurement (= 0 dose) (Fig. 1). Local oATP treatment
was significantly less efficient than both oral and intrave-
nous treatments in reducing hyperalgesia (Fig. 1). We
decided to use the minimal dose displaying the maximal
intravenous effect (e.g. 100 µM) of oATP in the following
experiments. Time 0 corresponds to oATP injection. Local
intraplantar injection of oATP in rat inflamed paws (3
hours after carrageenan injection) induced a significant
increase in paw withdrawal latencies after 1 hour of treat-
ment. Such increase was maintained in time (e.g. at 3, 6,
12 and 24 hours from treatment) compared with time 0
(Fig. 2a). Oral and intravenous administration of oATP
induced significantly higher antihyperalgesic effect than
local injection. Such effect was very evident after 3 hours
of treatment, improved in the following 9 hours and
slightly decreased after 24 hours (Fig. 2b and 2c,
respectively)
In Fig. 3 the antihyperalgesic effect exerted by oATP
(orally or intravenously injected) is compared to the effectBMC Immunology 2005, 6:18 http://www.biomedcentral.com/1471-2172/6/18
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exerted by diclofenac or indomethacin used at the same
dose. Data show that the antihyperalgesic activity of oATP
is significantly more elevated than that of diclofenac and
indomethacin.
Histologic expression of P2X7 receptors and HIS36
Each data is representative of 5 different performed exper-
iments for each treatment. As reported in Fig. 4, an intense
expression for P2X7 receptors was observed in nerve end-
ings and peripheral nerves of control saline-treated rat
hind paws. A similar result, but seldom and focally less
intense, was observed in peripheral nerves in hind paws
treated with carrageenan. In all specimens treated with
carrageenan, an irregularly diffuse inflammatory infiltrate
was present, with a prevalence of granulocytes and a vari-
able amount of lympho-histiocytic cells displaying a weak
and focal P2X7 positivity.
Hind paws treated with intravenous oATP, alone or after
inflammatory reaction induced by carrageenan, presented
a reduced expression of P2X7, either in nerves, or close to
epidermidis, in dermis or intramuscolar. Few arterial ves-
sels had a weak P2X7 positivity with a more prominent
reduction in P2X7 expression in areas close to the inflam-
mation site. Focally groups of cells with lympho-histio-
cytic cell morphology showed a strong cytoplasmatic
granular positivity for P2X7.
Treatment with local oATP, alone or after inflammatory
reaction induced by carrageenan, showed a focal, irregular
and mild reduction of P2X7 expression, often more prom-
inent in areas with phlogosis both in nerves and in vessels.
In all specimens sweat glands revealed a faint but fairly
diffuse P2X7 positivity.
Medium size isolated round cells with strong positivity for
HIS36 and identified as macrophages were often present
in a perivascular pattern in the dermis and subcutis of
hind paws. They were more frequent in tissues with carra-
geenan treatment only (as reported in Fig. 5), few in rat
hind paws with oATP local or intravenous administration
and very few in those with saline only (data not shown).
No differences in intensity or cellular immunostaining
distribution were observed among the experiments. The
summary of the immunohistochemical results are
reported in table 1.
Chemokine immunofluorescence expression
Clinical findings about the development of a local inflam-
mation in hind paws by carrageenan and the antiinflam-
matory effects of oATP were supported by
immunofluorescence assessment of the presence of three
inflammatory chemokines, commonly involved in
inflammation-dependent immune response phenomena:
MCP-1, IL-8 and IP-10. In all the processed rat paws,
cytokine expression was confirmed in dermis and always
absent in epidermidis. Any relevant expression of MCP-1
was not observed by confocal microscopy in the analyzed
bioptic samples, excluding a weak label of arteriolar
endothelium and isolated cells in reticular dermis in
carrageenan inflamed specimen sections (data not
shown). The control, submitted to saline only, failed to
show fluorescent signals for all the three cytokines on
Reduction by oATP (used at the doses of 50, 100 and 200  µM, dissolved in 0.15 ml saline) of inflammatory pain in rat  paws, as measured by paw withdrawal latency to a radiant  heat stimulus, following the administration of carrageenan Figure 1
Reduction by oATP (used at the doses of 50, 100 and 200 
µM, dissolved in 0.15 ml saline) of inflammatory pain in rat 
paws, as measured by paw withdrawal latency to a radiant 
heat stimulus, following the administration of carrageenan. 
Results are expressed as the mean ± SEM with n = 7 rats per 
group. * p < 0.05 compared with dose 0; ^ p < 0.05 com-
pared with local administration at the same dose. All values 
were significantly higher in oATP-treated paws (circle) than 
in saline-treated paws (triangle).BMC Immunology 2005, 6:18 http://www.biomedcentral.com/1471-2172/6/18
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both papillary and reticular layers of the dermis (Fig. 6a).
Conversely, carrageenan-treated rat hind paw section
samples expressed both IL-8 and IP-10 on dermis infiltrat-
ing cells, but not on vessel walls (Fig. 6b). A low expres-
sion of IP-10 on papillary dermis cells was observed on
hind paws from rats treated with oATP alone, following
either local (Fig. 6e) or intravenous injection (Fig. 6f). The
IP-10 appeared co-localized with IL-8 on small vessel wall
of dermis reticular layer in specimens from rat paws carra-
geenan-injected, then submitted to oATP local treatment
(Fig. 6c). No significant chemokine labeling was assessed
on specimens upon local treatment of rat paws with carra-
geenan and intravenous injection of oATP (Fig. 6d). The
intravenous administration of oATP seemed more effec-
tive then the local injection in reducing the expression of
chemokines in carrageenan-inflamed hind paws, accord-
ing to clinical findings.
Discussion
The hypothesis that ATP is a pain mediator [28] has sup-
ported the studies on its P2X receptors. Recently, ATP-
mediated mechanical hyperalgesia has been shown to be
decreased by the use of P2X3 receptor antagonists [29].
Based on our previous reports of the antinociceptive activ-
ity of oATP at the level of the hind paws in rats treated
intraplantarly with CFA [3], we investigated the therapeu-
tic effect of oATP in another model of rat paw inflamma-
tion, carrageenan-induced. The extracellular ATP released
in inflamed tissues has pronociceptive activity [30,31]: it
possibly acts by binding and activating the P2X receptors
for ATP present on pain-sensing neurons. In addition,
since P2X7 receptors are localized on many tissue
components involved in inflammation, the binding and
activation of such receptors by ATP could enable the same
structures to release proinflammatory and pronociceptive
mediators. Local treatment with oATP abrogates inflam-
matory pain possibly by inhibiting P2X7 receptors for ATP
which are localized on nerve terminals and on vessels
[2,3].
Paw inflammation is a multifactorial response due to
proinflammatory chemokines which are responsible for
the infiltration and activation of various leukocyte popu-
lation in joint tissue. We analysed in parallel the expres-
sion of some chemokines (MCP-1, IP 10 and IL 8) and the
expression of P2X7 receptors in the same inflamed tissues
and their modifications due to oATP treatment. The anal-
ysis of the chemokine presence had the aim to evaluate
wheter the use of oATP was able to influence the recruit-
ment of circulating leukocytes. This feature was not
shown by IL-lβ, a cytokine produced by activated
macrophages, which fails to display chemoattractant
properties, indicating only the state of macrophage activa-
tion. The three selected chemokines are described to be
able to recruit the principal inflammatory cells:
a) Withdrawal latencies measured 3 hours after intraplantar carrageenan injection (basal measurement = time 0) and at differ- ent hours following oATP (100 µM in 0.15 ml saline, continuous line) or 0.9% saline (0.15 ml, hatched line) local intraplantar  injection (circle) Figure 2
a)Withdrawal latencies measured 3 hours after intraplantar carrageenan injection (basal measurement = time 0) and at differ-
ent hours following oATP (100 ( µM in 0.15 ml saline, continuous line) or 0.9% saline (0.15 ml, hatched line) local intraplantar 
injection (circle). Mean ± SEM of 7 rats. * p < 0.05 compared to saline at the same time. b) Withdrawal latencies measured 3 
hours after intraplantar carrageenan injection (basal measurement = time 0) and at different hours following oATP (100 µM in 
0.15 ml saline, continuous line) or saline (0.15 ml, hatched line) oral administration (square). Mean ± SEM of 7 rats. * p < 0.05 
compared to saline at the same time. c) Withdrawal latencies measured as previously (3 hours after local carrageenan injection 
= time 0) and at different hours of oATP (100 µM in 0.15 ml saline, continuous line) or saline (0.15 ml, hatched line) intrave-
nous administration (triangle). Mean ± SEM of 7 rats. * p < 0.05 compared to saline at the same time.BMC Immunology 2005, 6:18 http://www.biomedcentral.com/1471-2172/6/18
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granulocytes (IL-8), monocytes/macrophages (MCP-1)
and T lymphocytes (IP-10).
Our clinical results indicate that: 1) local treatment with
oATP significantly relieves inflammatory pain in carra-
geenan-induced paw inflammation model, as in
previously reported CFA model [3]; 2) oral and intrave-
nous treatments with oATP are more efficient than local
treatment in reducing the inflammatory pain; 3) intrave-
nous treatment is more efficient than oral treatment; 4)
the antinociceptive activity of a single dose of oATP lasts
24 hours; 5) the antinociceptive activity of oATP is more
evident than that due to diclofenac or indomethacin in
our experimental model. Based on the increased antinoc-
iceptive effect due to oATP intravenously administered
with respect to that orally administered, we studied the
expression of P2X7 receptors and of chemokines in
inflamed tissues following local or intravenous oATP
administration, e.g. in conditions of minimal or maximal
antihyperalgesic oATP effect.
P2X7 receptors are involved in several processes concern-
ing immunomodulation and inflammation. Previous
reports show that the absence of P2X7 receptors alters
cytokine production and leukocyte function and attenu-
ates the inflammatory response [32,33]. In fact, high ATP
concentrations were unable to promote IL-lβ extracellular
accumulation from lypopolysaccharide (LPS)-activated
blood samples derived from P2X7 receptor-deficient
mice, in contrast with blood samples obtained from wild-
type. In addition, P2X7 receptor-deficient mice were pro-
tected against clinical signs of mAb-induced arthritis [33].
Recent data indicate that, in response to ATP binding, the
P2X7 receptors facilitate cation channel activation, non-
specific pore formation, rapid changes in plasma mem-
brane morphology (blebbing) and secretion of IL-1β from
LPS-primed macrophages [34]. The "blebbing" induced
by ATP was blocked by oATP. Blebbing was abrogated in
the presence of Rho-effector kinase inhibitors, whereas
ATP-induced IL-lβ release was unaffected, suggesting dif-
ferent signalling pathways for P2X7 receptors. In addition,
the P2X7 receptor-protein complex comprises several dis-
tinct identified proteins, with different regulatory
capacities [35], indicating a complexity for the P2X7
receptor functions.
We showed the antinociceptive activity of oATP, which is
able to block the P2X7 receptor [1], in rats bearing acute
paw inflammation. The question arises about the mecha-
nisms by which the oATP-induced inhibition of P2X7
receptor activation are able to relieve inflammatory pain.
Our previous data suggested the possibility that the block
of P2X7 receptors expressed by nerve terminals could be
useful to inhibit pain transmission [3]. In inflamed paws
the expression of P2X7 receptors was less evident in oATP-
treated than in untreated rats, independently on the route
of oATP administration. Noteworthly, such expression
was reduced at the level of nerve terminals and of vessels
close to inflammation site, more than at the level of the
immune cells (see Fig. 4 and 5). The expression of MCP-1
a) Withdrawal latencies measured 24 hours after intraplantar  carrageenan injection (basal measurement = time 0) and after  different hours from oATP (circle), or diclofenac (square), or  indomethacin (triangle) oral administration (100 µM in 0.15  ml saline) Figure 3
a) Withdrawal latencies measured 24 hours after intraplantar 
carrageenan injection (basal measurement = time 0) and after 
different hours from oATP (circle), or diclofenac (square), or 
indomethacin (triangle) oral administration (100 µM in 0.15 
ml saline). Mean ± SEM of 7 rats. *p < 0.05 compared to 
diclofenac or indomethacin at the same time. b) Withdrawal 
latencies measured 24 hours after intraplantar carrageenan 
injection (basal measurement = time 0) and after different 
hours from oATP (circle), or diclofenac (square), or 
indomethacin (triangle) intravenous injection (100 µM in 0.15 
ml saline). Mean ± SEM of 7 rats. *p < 0.05 compared to 
diclofenac or indomethacin at the same time.BMC Immunology 2005, 6:18 http://www.biomedcentral.com/1471-2172/6/18
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Immunohistochemistry of P2X7 receptors Figure 4
Immunohistochemistry of P2X7 receptors. Hind paw sections from control rats treated with saline (a) or oATP locally (c) or 
intravenously (e). After carrageenan induced inflammation, hind paws were submitted, to either saline (b), oATP local (d) or 
oATP intravenous (f) treatment. Notice the strong labelling on nerves and vessels in specimens treated only with saline, with 
variable presence of P2X7 which shows a general reduction after oATP local treatment, more evident after intravenous oATP 
treatment (original magnification 200x, P2X7 evidenced in brown, 3,3 diaminobenzidine, PGP 9.5 evidenced in blue, nithroblue 
tetrazolium). Data are representative of 5 experiments.BMC Immunology 2005, 6:18 http://www.biomedcentral.com/1471-2172/6/18
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was weakly evident only in carrageenan-inflamed rat paws
at the level of arteriolar endothelium and of some dermal
cells; in the same structures we observed by immunohis-
tochemistry an increased number of macrophages (HIS36
positive cells). MCP-1 was absent and only few macro-
phages were present in paws from oATP-treated rats.
These data confirm the strict correlation between P2X7
expression by leukocytes and relative inflammatory
response and underline that the reduction of inflamma-
tory effects due to oATP administration is similar to that
observed in P2X7 receptor deficient mice [33]. Carra-
geenan-treated rat paws expressed IL-8 and IP-10 on der-
mal infiltrating cells, whereas a low expression of IP-10 on
dermal cells followed oATP treatment alone (both local
and intravenous). IP-10 and IL-8 were co-localized on the
wall of small vessels in carrageenan-inflamed paws of
intraplantarly oATP-treated rats. Moreover, no chemokine
label was observed in carrageenan-inflamed paws of intra-
venously-oATP-treated rats. Such results indicate that
oATP treatment significantly reduced chemokine expres-
sion at vascular rather than at infiltrating cell level. In fact
oATP local treatment of carrageenan-inflamed paws com-
pletely abrogated MCP-1 expression, whereas the intrave-
nous treatment with oATP abrogated the expression of all
the three chemokines in inflamed paws. In particular, the
abrogation of MCP-1 production by oATP could be
related to the oATP-induced block of P2X7 function on
activation of endothelial and immune cells, which can
become ineffective to produce MCP-1.
In our results we underline the relation between the
absence of recruited macrophages and the absence of
MCP-1 expression in the inflamed paws of intravenously
oATP-treated rats.
Other studies demonstrate the presence of P2X7 receptors
on nervous and vascular structures. In fact, P2X7 immu-
noreactivity has been shown in rats at the level of glial
cells of gastrointestinal musculature, in mienteric and
submucosal ganglia (where perineuronal nerve endings
appeared brightly labeled) [36]. In addition, pharmaco-
logical identification of P2X1, P2X4 and P2X7 nucleotide
receptors has been evidenced in the smooth muscle of
human umbilical cord and chorionic blood vessels [37].
Moreover, LPS-activated endothelial cells have been
shown able to secrete ATP, via P2X7 receptors, and to
release IL-lα [38].
During carrageenan-induced acute inflammation ATP is
released by damaged cells. When ATP activates cells
involved in the inflammatory process and bearing P2X7
receptors, other mediators and ATP molecules are released
by these cells. Indeed, oATP could block such amplifying
mechanism of inflammation and also downregulate P2X7
receptor expression, especially in vessels and nerves close
to the site of inflammation (see Fig 4). This hypothesis is
supported by the fact that chemokine expression is
reduced by oATP treatment. We hypothesize that oATP, by
blocking the P2X7 receptors present on nerves and
endothelial cells, could regulate some effects of ATP (hav-
ing pronociceptive functions when released) on these
structures. The effect of oATP was greater when given
orally or intravenously instead of locally, possibly because
the oral and intravenous administrations of oATP could
permit its systemic diffusion. Thus oATP could reach sites
distal to the site of inflammation and so enhance the con-
tact with circulating leukocytes bearing P2X7 receptors.
Such contact favours the inactivation of immune cells,
which are able to produce inflammatory pronociceptive
mediators. In addition, the most antinociceptive activity
obtained when oATP was intravenously injected (instead
of locally or orally) could indicate that the molecule
crosses the blood-brain barrier and that it may also have
central effects and not only peripheral effects. It is also
possible that oATP blocks other receptors than P2X7, e.g.
P2X1 and P2X2 [4]. Effectively, human P2X1 and P2X7
receptors are co-expressed in several cell types such as lym-
phocytes or epithelial cells [39], and oATP was found to
be ineffective in separating P2X1 receptor current from the
P2X7 current. In addition, none oATP activity on P2X4
has been reported. However, the involvement of P2X7 is
also assured by the fact that P2X3-/- mice did not display
Presence of macrophages in rat inflamed paw section Figure 5
Presence of macrophages in rat inflamed paw section. In der-
mis and subcutis of carrageenan-treated hind paw a discrete, 
focal macrophagic (HIS36positive cells) infiltration is present 
(original magnification 250x; HIS36 evidenced with Dab). 
Dataare representative of 5 experiments.BMC Immunology 2005, 6:18 http://www.biomedcentral.com/1471-2172/6/18
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a difference in thermal hyperalgesia to wild type controls
in the carrageenan model of inflammation [40]. Our data
suggest that the potential analgesic and also the anti-
inflammatory properties of oATP might have significant
therapeutic potential in reducing inflammatory pain. In
addition, the more efficient antinociceptive activity of
oATP with respect to that of some known NSAIDs is help-
ful, in consideration of NSAID direct cytotoxic effects
[41].
Recently, it has been demonstrated that oATP can reduce
pro-inflammatory TNFα-induced signalling in HEK293
cells, that lack of P2X7 expression. Such and other
reported results possibly indicate that oATP interfere with
the activation of signalling pathways involved in the
inflammatory response, independently on oATP action
on P2X receptors [42], thus showing a mechanism inde-
pendent of the expression or activation of known P2
receptor subtypes. However, the involvement of the P2X7
receptors in the inflammatory pain has been suggested by
other results [43]. In fact, mice lacking P2X7 receptors did
not display inflammatory and neuropathic hypersensitiv-
ity to both mechanical and thermal stimuli and were
impaired in the ability to release IL-1 beta, IL-10 and
MCP-1, the latter in agreement with our findings,
obtained with the administration of oATP in rats bearing
paw inflammation. All data suggest that P2X7 receptors
exert a role in both acute and chronic inflammations.
Conclusion
Our results show that oATP systemically administered
removes hyperalgesia induced by carrageenan in rat paws.
Tha data suggest the possible use of oATP to reduce the
inflammatory pain.
Methods
Animals
The procedures followed the guidelines of the Interna-
tional association for the Study of Pain [24]. Male Wistar
rats from Harlan Italy (Corezzana, Milano, Italy) weigh-
ing about 250 g were used. They were housed in groups of
three per cage, allowed free access to water and food and
exposed to a 12/12-hour light/dark cycle, and
acclimatised to the laboratory at least 5 days prior to the
experiments.
Induction of inflammation
Following brief exposure to halothane (5%) anesthesia
(Hoechst, Milano, Italy), inflammation was induced by
the injection of 0.1 ml 1% carrageenan (λ-carrageenan,
Sigma-Aldrich, Milan, Italy) in sterile saline in the right
hind paw of the rats. Maximal incidence of inflammation
(e.g. the hind paw edema) occurred 3 hours after carra-
geenan injection, as previously reported [25].
Administration of oATP
Three hours following carrageenan injection, the rats were
treated with oATP (Sigma-Aldrich) dissolved in 0.15 ml
sterile saline, whereas control rats received the drug
vehichle alone (0.15 ml sterile saline). Firstly, 3 different
doses oATP (50 µM, 100 µM, 200 µM, in 0.15 ml, respec-
tively) were administered: 1) locally, by intraplantar injec-
tion in the right hind paw; 2) orally, by using an orogastric
catheter; 3) intravenously, through the left femoral vein.
The injections were performed under brief halothane
anestesia and the antinociceptive effect of oATP was meas-
ured 3 hours following its administration. Since a more
significant antihyperalgesic effect was observed by using
100 µM oATP (see Results section), such dose was selected
among the tested doses to perform further experiments.
To perform histologic evaluations (by
immunohistochemistry or by confocal analysis), oATP
was administered locally or intravenously; in fact, as
shown in the Results section, these routes of administra-
tion respectively showed minimal or maximal antihyper-
algesic effect (as clinically evidenced).
Reduced thermal hyperalgesia measure
The observers of the thermal hyperalgesia measurements
were blinded. The method of Hargreaves was used to
Table 1: Immunohistochemical results in rat hind paws after induction of inflammation by carrageenan
Treatment P2X7 receptor nerve 
expression
P2X7 receptor vascular 
expression
P2X7 receptor expression 
in lympho-histiocytic cells
Quantity of macrophages 
(HIS36+)
Saline only Strong Strong Weak Very few
Carrageenan only Strong, locally moderate Strong, focally moderate Weak Focally in discrete amount
Carrageenan + OATP 
intraplantar injection
Moderate to weak Moderate to weak Weak to moderate Few
Carrageenan + oATP 
intravenous administration
Weak to absent Very weak (absent in area 
close to inflammatory 
infiltrate)
Moderate, focally strong Few
Note. A discrete amount of granulocytes are present in carrageenan-treated hind paws.BMC Immunology 2005, 6:18 http://www.biomedcentral.com/1471-2172/6/18
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assess the hind paw nociceptive thresholds to thermal
stimuli [26]. We used a plantar test apparatus (Ugo Basile,
Comerio, Italy). Briefly, the rats were placed in a clear
plastic chamber and left to acclimatize for 5 minutes
before testing. Radiant heat stimulus was induced by light
from a 8 V-50 W halogen bulb (64607 OSRAM), delivered
to the plantar surface of the rat's hind paw through the
base of the plastic box; the beam was about 12 mm in
diameter. The rats were familiarized with the handling
procedure 3 days before the antinociceptive test. Time
taken by the animal to withdraw its right hind paw was
measured before and after oATP injection. Reduced ther-
mal hyperalgesia was defined as a significant increase in
the withdrawal latency compared to the basal measure-
ment. The values of thermal hyperalgesia were deter-
mined at 1, 3, 6, 12 and 24 hours after oATP injection. The
same procedure was used to test the antihyperalgesic
effect of diclofenac and indomethacin orally or intrave-
nously administered at the same dose of oATP (e.g. l00
µM in 0.15 ml saline)
Confocal analysis
Rat right hind paws were sampled and processed for cryo-
static inclusions. For any treatment, 5 different experi-
ments were performed. The treatments included: saline,
carrageenan, oATP alone, and carrageenan ± local or intra-
venous oATP administration. The same hind paws were
also used for immunohistochemistry.
Biopsies were fixed in 4% paraformaldehyde in Dul-
becco's PBS (DPBS) then cryoprotected in 20% sucrose in
DPBS, embedded in Tissue Tek medium and snap-frozen
by immersion in liquid nitrogen. Pseudo-seriated l0 µm
thick sections were submitted to indirect immunofluores-
cence staining by using mouse monoclonal antibodies
(mAbs) against mouse α MCP-1 (B-B4 RPE, Groningen,
The Netherlands)ÙIP-10 (Peprotech EC Ltd., London,
UK), and IL-8 (Pharmingen, San Diego, CA). The sections
were incubated in blocking solution (1% BSA in DPBS, 30
minutes, RT), then in primary Ab diluted in blocking solu-
tion (2 hours, RT), finally, after 30 minutes of DPBS wash-
ing, in conjugated secondary Ab (Rabbit-anti-Mouse Ig-
FITC conjugated, DAKO, Milano, Italy) in DPBS (30 min-
utes, RT). Double staining was realized by superposing
the same procedure with a different primary Ab and a
TRITC-labelled secondary Ab. The 3 possible couplings of
primary Abs were tested and single staining served as con-
trols. DAPI nuclear staining (0.2 nM, 20 minutes, RT) fol-
lowed the immunostaining steps.
The sections, mounted with Fluorsave (Calbiochem,
Merck Eurolab Srl, Milano, Italy) were analysed with the
support of a confocal microscope Leica TCS SP2 (Leica
Microsystems, Heidelberg, GmbH); 3D maximum projec-
tions were obtained from single channel-collected series
of images, subsequently they were superposed by Adobe
Photoshop software.
Immunohistochemistry
Materials and methods for immunostaining have been
previously described [3]. Immunostain was perfomed on
Confocal microscopy on rat paws Figure 6
Confocal microscopy on rat paws. The sections are doubly 
labeled with anti- IP-10 and IL-8 mAbs revealed by FITC- 
(green) or TRITC- (red) conjugated secondary Abs respec-
tively. Merged Free Projection Max of images seriesshows 
cytokine expression after saline (a), carrageenan (b), carra-
geenan+oATP local treatment (c), carrageenan+oATP intra-
venous treatment (d), local oATP treatment (e), intravenous 
oATPtreatment (f). Nuclei are stained with DAPI (blue) 
(original magnification 400x). Notice thepresence of acti-
vated cells in the derma in b and f, the endoluminal signal in 
dermal small vessels(a, c, e) and the absence of cytokine labe-
ling in d (original magnification 400x).BMC Immunology 2005, 6:18 http://www.biomedcentral.com/1471-2172/6/18
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all specimens by using two different procedures. Sections
(4  µm-thick) were prepared on slides pretreated with
poly-L-lysine (Sigma Diagnostic Inc., St Louis, USA). A
double staining method was applied to examine the
relationship between P2X7 and cutaneous nerve fibers
using anti-P2X7 receptor purified polyclonal antibody
(Chemicon International, Inc., Temecula, CA) and the
monoclonal antibody Protein Gene Products 9.5 (Novo-
castra Laboratories Ltd, Newcastle, UK). The anti-P2X7
polyclonal antibody was directed against a c-term anti-
body (epitope 567–595), which has been previously
shown highly selective [27]. Binding was revealed by 3',3'-
diaminobenzidine (Liquid Dab, BioGenex, San Ramon,
CA) for P2X7 receptor and by 5-bromochloroindoxyl
phosphate and nitro blue tetrazolium chloride (DAKO,
Copenhagen, Denmark) for PGP 9.5. The two procedures
were performed alternatively, on both antibodies. Sec-
tions were counterstained with Green Light. To obtain a
negative control, the primary antibodies were routinely
omitted.
In a separate setting of immunostainings we used a mouse
monoclonal antibody HIS36 (Santa Cruz, California,
USA) specific for rat macrophage subset. All the immu-
nostained slides were viewed in a blinded fashion.
Statistical analysis
The withdrawal latency data (expressed as mean ± SEM)
were analyzed using a two-way analysis of variance fol-
lowed by Dunnett's test. Significance was assumed when
P < 0.05.
Abbreviations
oATP, periodate oxidized ATP; MCP-1, monocyte chem-
oattractant protein-1; VEGF, vascular endothelial growth
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